Sanofi bucks unit-sale trend with plan to unload $7B worth of older products

Sanofi CEO Chris Viehbacher

While other companies are hiving off large pieces of their operations to get fit and focused, Sanofi ($SNY) has decided to simply clean out its closet. By selling off a number of older products, it can make room for the kind of bolt-on deals that CEO Chris Viehbacher said on Tuesday interest him. Report

Suggested Articles

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.